Ariad Pharmaceuticals, Inc.
) recently presented pre-clinical data on AP26113. The data
presented by the company revealed that AP26113 can inhibit
clinically relevant anaplastic lymphoba kinase (ALK) mutants
) Xalkori (crizotinib) and oncogenic repressor of
silencing-1(ROS1) fusions in patients suffering from non-small
cell lung cancer (NSCLC).
Ariad expects to begin enrollment for a pivotal study on
AP26113 in ALK-positive NSCLC patients resistant to Xalkori, in
the third quarter of 2013.
In Sep 2012, Ariad had announced initial clinical results from
a phase I/II study on AP26113. The study is being conducted to
determine the maximum tolerated dose as well as the recommended
dose for conducting additional studies on the candidate.
Moreover, safety issues and preliminary anti-tumor activity are
also being evaluated. The safety data from the study revealed
that candidate was well-tolerated.
The company anticipates to move into four phase II expansion
cohorts in the second quarter of 2013. One study is designated
for epidermal growth factor receptor (EGFR)-mutant NSCLC
The company also has plans to evaluate AP26113 for ALK
positive NSCLC patients with brain metastases.
We remind investors that companies like
Roche Holding AG
) have a presence in the NSCLC market. In Sep 2011, Tarceva
received approval from the European Commission for the treatment
of a specific type of NSCLC in Europe.
Currently, Ariad carries a Zacks Rank #3 (Hold).
Comparatively, other companies like
) look more attractive. UCB carries a Zacks Rank #1 (Strong
ARIAD PHARMA (ARIA): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.